Vertex Pharmaceuticals (VRTX) is a publicly traded Healthcare sector company. As of July 5, 2026, VRTX trades at $528.04 with a market cap of $134.02B and a P/E ratio of 31.04. VRTX moved +6.03% today. Year to date, VRTX is +16.38%; over the trailing twelve months it is +15.54%. Its 52-week range spans $362.50 to $529.14. Analyst consensus is strong buy with an average price target of $562.95. Rallies surfaces VRTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
FDA Clears Casgevy for Sickle Cell in Ages 2+, Vertex Shares Surge: FDA approval extends Casgevy use to sickle cell patients aged two and older, lowering the minimum treatment age from 12 and broadening the pediatric eligibility. Vertex and CRISPR shares surged on the expanded label, boosting expectations for accelerated enrollment and higher long-term revenue potential.
| Metric | Value |
|---|---|
| Price | $528.04 |
| Market Cap | $134.02B |
| P/E Ratio | 31.04 |
| EPS | $17.01 |
| Dividend Yield | 0.00% |
| 52-Week High | $529.14 |
| 52-Week Low | $362.50 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $12.22B |
| Net Income | $4.34B |
| Gross Margin | 86.24% |
24 analysts cover VRTX: 0 strong buy, 19 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $562.95.